여성 건강 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 약물 종류별, 연령별, 지역별, 부문별 예측(2025-2030년)

Women´s Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Menopause), By Drug Class (Hormonal Therapies, Pain And Symptom Management), By Age (50 Years And Above), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

여성 건강 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 여성 건강 시장 규모는 2025-2030년 연평균 5.1%의 성장률을 기록하여 2030년에는 685억 3,000만 달러에 달할 것으로 예상됩니다.

혁신적인 신제품 출시와 여성 건강 관련 강력한 파이프라인의 존재는 시장 성장을 촉진하는 주요 요인입니다. 예를 들어, 2021년 5월 식품의약국은 화이자가 미오반트 사이언스와 공동 개발한 월경과다 출혈을 동반한 자궁근종 치료제 마이펨브리를 승인했습니다. 자궁내막증 발병률 증가와 비영리 단체의 지원 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

예를 들어, 빌 & 멜린다 게이츠 재단은 새로운 피임 기술 개발과 가족 계획 이니셔티브를 지원하기 위해 2021-2030년까지 매년 2억 8천만 달러를 기부하기로 약속했으며, WHO의 2021년 보고서에 따르면 전 세계 가임기 소녀와 여성의 약 10%(1억 9천만 명)(1억 9,000만 명)이 자궁내막증을 앓고 있습니다. 자궁내막증은 생리통, 배변통, 복부 팽만감, 메스꺼움, 피로감 등을 동반하는 만성질환으로, COVID-19 팬데믹은 시장에 부정적인 영향을 미쳤으며, SARS-CoV-2의 확산을 억제하기 위해 정부가 시행한 사회적 거리두기 및 지역 봉쇄와 같은 엄격한 조치는 치료 시설과 부인과 클리닉에 부정적인 영향을 미쳤습니다.

예를 들어, 중저소득 국가에서는 장시간 및 단시간 작용하는 가역적 피임약의 사용이 감소하고 있습니다. 제품 개발 및 상용화를 위해 주요 기업들이 공동 연구, 계약 및 제휴와 같은 전략적 노력을 기울이는 것은 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 10월 리히터와 히크마는 Xgeva와 Prolia의 바이오시밀러인 데노수맙의 미국 내 상용화를 위한 독점 라이선스 계약을 체결했습니다. 또한, 제네릭 의약품과의 경쟁 심화는 특허 만료 후 가격 압력을 증가시켜 시장 성장을 억제할 것으로 예상됩니다.

예를 들어, 특허가 만료된 포르테오의 매출은 2020-2021년 23% 감소했으며, 2021년 세계 시장은 북미가 유리한 상환 정책, 주요 시장 기업의 존재, 정부의 우호적인 규제, 제품 승인 및 상용화, 높은 여성 피임약 사용률 등으로 인해 우위를 점했습니다. 아시아태평양은 여성 건강에 대한 정부 지출 증가로 인해 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 예를 들어, 호주 정부는 보건 서비스 및 지원을 지원하기 위해 3억 3,300만 달러의 투자를 발표했습니다.

여성 건강 시장 보고서 하이라이트

• 피임약 부문은 가족계획에 대한 인식의 증가와 피임법의 지속적인 기술 발전에 힘입어 2024년 세계 매출의 35.07% 이상을 차지하며 가장 높은 매출 비중을 차지했습니다.
• 호르몬 요법 부문은 2024년 시장을 주도하고 예측 기간 동안 가장 빠른 성장률을 보일 것으로 예상됩니다.
• 기타(50세 미만) 부문은 2024년 시장을 장악하고 예측 기간 동안 그 지위를 유지할 것으로 예상되며, 50세 미만 여성은 자궁내막증, 호르몬 불임, 다낭성난소증후군 등 불임과 관련된 문제에 직면할 가능성이 높습니다.
• 북미 여성 건강 시장은 2024년 43.04%의 점유율로 세계 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 여성 건강 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 여성 건강 시장 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석

제4장 여성 건강 시장 : 용도 추정·동향 분석

• 용도 시장 점유율(2024년·2030년)
• 부문 대시보드
• 세계의 여성 건강 시장 : 용도 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석
  • 호르몬성 불임
  • 피임약
  • 폐경후 골다공증
  • 자궁내막증과 자궁근종
  • 폐경
  • 다낭성난소증후군(PCOS)

제5장 여성 건강 시장 : 약물 종류 추정·동향 분석

• 약물 클래스 시장 점유율(2024년·2030년)
• 부문 대시보드
• 세계의 여성 건강 시장 : 약물 종류 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석
  • 호르몬요법
  • 뼈 건강 촉진제
  • 불임 치료제
  • GnRH 모듈레이터
  • 통증과 증상 관리
  • 대사제
  • 기타

제6장 여성 건강 시장 : 연령 추정·동향 분석

• 연령 시장 점유율(2024년·2030년)
• 부문 대시보드
• 세계의 여성 건강 시장 : 연령 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석
  • 50세 이상
  • 기타

제7장 여성 건강 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석(2024년·2030년)
• 지역 시장 대시보드
• 세계의 지역 시장 현황
• 시장 규모와 예측 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석 : 2024년
  • AbbVie, Inc.
  • Bayer AG
  • Merck &Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Agile Therapeutics
  • Amgen, Inc.
  • Apothecus Pharmaceutical Corp.
  • Blairex Laboratories, Inc.
  • Ferring BV

ksm

영문 목차

영문목차

Women's Health Market Growth & Trends:

The global women's health market size is expected to reach USD 68.53 billion by 2030, registering a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women's health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women's health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Women's Health Market Report Highlights:

• The contraceptives segment held the highest revenue share of more than 35.07% of the global revenue in 2024, spurred by rising awareness of family planning and ongoing technological advancements in contraceptive methods.
• Hormonal therapies segment led the market in 2024 and is expected to grow at fastest growth rate over the forecast period.
• The others (below 50 years) segment dominated the market in 2024 and is expected to sustain the position for the forecast period. Women aged below 50 years are more likely to face issues associated with fertility, such as endometriosis, hormonal infertility, and polycystic ovary syndrome.
• The North America women's health market dominated the global market with a share of 43.04% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Age
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Drug class outlook
  • 2.2.3. Age outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Women's Health Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of target diseases
    • 3.2.1.2. Increasing initiatives by government and various organizations
    • 3.2.1.3. Rising publicly funded family planning services
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Patent expiry of major drugs
    • 3.2.2.2. Lawsuits related to products
    • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices
• 3.3. Women's Health Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Women's Health Market: Application Estimates & Trend Analysis

• 4.1. Application Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Women's Health Market by Application Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Hormonal infertility
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Contraceptives
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Postmenopausal osteoporosis
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Endometriosis & uterine fibroids
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Menopause
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Polycystic ovary syndrome (PCOS)
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Women's Health Market: Drug Class Estimates & Trend Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Women's Health Market by Drug Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hormonal Therapies
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Bone Health Agents
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Fertility Agents
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. GnRH Modulators
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Pain and Symptom Management
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Metabolic Agents
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Others
    • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Women's Health Market: Age Estimates & Trend Analysis

• 6.1. Age Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Women's Health Market by Age Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. 50 years and above
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2. Postmenopausal osteoporosis
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3. Endometriosis & uterine fibroids
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.4. Menopause
      • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.5. Others
      • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Others
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Women's Health Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. AbbVie, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bayer AG
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Pfizer, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Teva Pharmaceutical Industries Ltd.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Agile Therapeutics
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Amgen, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Apothecus Pharmaceutical Corp.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Blairex Laboratories, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Ferring B.V.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료